Literature DB >> 3046368

Perturbation of cultured human endothelial cells by atherogenic levels of low density lipoprotein.

J A Holland1, K A Pritchard, N J Rogers, M B Stemerman.   

Abstract

Cultured human umbilical vein endothelial cells (EC) exposed to atherogenic levels of low density lipoprotein (LDL) for protracted periods demonstrated no measurable evidence of overt cytotoxicity, but were perturbed as indicated by an increase in prostacyclin (PGI2) production. Confluent EC were incubated with high LDL concentrations (240 or 330 mg/dl cholesterol) for 1 to 12 days. LDL was added to culture media containing 25% human lipoprotein-deficient serum to determine the effects of LDL independent of other lipoproteins. LDL did not injure EC as assessed by cell count, vital dye exclusion, 51chromium release, and lactate dehydrogenase release. Although high concentrations of LDL did not cause EC cytotoxicity, such LDL concentrations did results in increased PGI2 generation. PGI2 accumulation in postincubation media was increased two-to-fivefold in otherwise unstimulated cells as measured by radioimmunoassay of the stable PGI2 breakdown product, 6-keto-PGF1-alpha. This elevation persisted for the entire 12-day exposure to high LDL concentrations. These results indicate that prolonged exposure to atherogenic concentrations of LDL does not effect EC viability, but does cause an endothelial perturbation as demonstrated by an increased PGI2 production.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3046368      PMCID: PMC1880753     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  21 in total

1.  Enzymatic conversion of prostaglandin endoperoxide H2 and arachidonic acid to prostacyclin by cultured human endothelial cells.

Authors:  A J Marcus; B B Weksler; E A Jaffe
Journal:  J Biol Chem       Date:  1978-10-25       Impact factor: 5.157

Review 2.  Prostacyclin and arterial wall biology.

Authors:  S Moncada
Journal:  Arteriosclerosis       Date:  1982 May-Jun

Review 3.  Prostacyclin in physiology and pathophysiology.

Authors:  J R Vane; S Bunting; S Moncada
Journal:  Int Rev Exp Pathol       Date:  1982

4.  In vitro correlates of endothelial injury and repair.

Authors:  H M Fillit; E A Jaffe; J B Zabriskie
Journal:  Lab Invest       Date:  1982-01       Impact factor: 5.662

5.  Fibronectin: purification, immunochemical properties, and biological activities.

Authors:  E Ruoslahti; E G Hayman; M Pierschbacher; E Engvall
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

6.  Enhanced rates of fluid pinocytosis during exponential growth and monolayer regeneration by cultured arterial endothelial cells.

Authors:  P F Davies; S C Selden; S M Schwartz
Journal:  J Cell Physiol       Date:  1980-02       Impact factor: 6.384

7.  An endothelial cell growth factor from bovine hypothalamus: identification and partial characterization.

Authors:  T Maciag; J Cerundolo; S Ilsley; P R Kelley; R Forand
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

8.  Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid.

Authors:  D W Morel; J R Hessler; G M Chisolm
Journal:  J Lipid Res       Date:  1983-08       Impact factor: 5.922

9.  Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187.

Authors:  B B Weksler; C W Ley; E A Jaffe
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

10.  Serial propagation of human endothelial cells in vitro.

Authors:  T Maciag; G A Hoover; M B Stemerman; R Weinstein
Journal:  J Cell Biol       Date:  1981-11       Impact factor: 10.539

View more
  13 in total

Review 1.  Leukocytes in glomerular injury.

Authors:  Stephen R Holdsworth; Peter G Tipping
Journal:  Semin Immunopathol       Date:  2007-10-16       Impact factor: 9.623

2.  Low density lipoproteins and Lovastatin modulate the organ-specific transendothelial migration of primary and metastatic human colon adenocarcinoma cell lines in vitro.

Authors:  N Mehta; J Hordines; D Sykes; R J Doerr; S A Cohen
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

Review 3.  Free radicals, reactive oxygen species and human disease: a critical evaluation with special reference to atherosclerosis.

Authors:  B Halliwell
Journal:  Br J Exp Pathol       Date:  1989-12

Review 4.  Nitric oxide, nitric oxide synthase, and hypertensive vascular disease.

Authors:  R Busse; I Fleming
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

Review 5.  Blood radicals: reactive nitrogen species, reactive oxygen species, transition metal ions, and the vascular system.

Authors:  V Darley-Usmar; B Halliwell
Journal:  Pharm Res       Date:  1996-05       Impact factor: 4.200

6.  Atherogenic concentrations of low-density lipoprotein enhance endothelial cell generation of epoxyeicosatrienoic acid products.

Authors:  K A Pritchard; P Y Wong; M B Stemerman
Journal:  Am J Pathol       Date:  1990-06       Impact factor: 4.307

7.  Atherogenic levels of low-density lipoprotein increase endocytotic activity in cultured human endothelial cells.

Authors:  J A Holland; K A Pritchard; N J Rogers; M B Stemerman
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

8.  Effect of ethanol on low density lipoprotein and platelet composition.

Authors:  J L Hojnacki; J E Cluette-Brown; R N Deschenes; J J Mulligan; T V Osmolski; N J Rencricca; J J Barboriak; J A Jakubowski
Journal:  Lipids       Date:  1991-11       Impact factor: 1.880

9.  Lipid peroxidation of isolated chylomicrons and oxidative status in plasma after intake of highly purified eicosapentaenoic or docosahexaenoic acids.

Authors:  J B Hansen; R K Berge; A Nordøy; K H Bønaa
Journal:  Lipids       Date:  1998-11       Impact factor: 1.880

10.  Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine.

Authors:  A Zembowicz; S L Jones; K K Wu
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.